https://repository.utm.md/handle/5014/26860 Mon, 20 Apr 2026 19:51:34 GMT 2026-04-20T19:51:34Z https://repository.utm.md/handle/5014/26954 Effects of beta-blockers on cardiac phenotypes REJIMON NAIR, Rahul; SIDORENKO, Ludmila Adrenergic β-blockers are medications that attach to β-adrenergic receptors without causing any activation. Rather, they obstruct the effects of β-adrenergic agonists and are employed in the management of several illnesses, including heart failure, stress, anxiety, angina pectoris, myocardial infarction, hypertension, headaches, migraines, and prostate cancer. In general, β-blockers alleviate symptoms and lower the chance of cardiovascular events. β-adrenergic blocking medications have been extensively employed in the treatment of heart failure because of their capacity to avert the negative effects of stimulation of the sympathetic system on the cardiovascular system and offer patients therapeutic advantages. A meta-analysis was conducted to examine the relationship between the Arg389Gly polymorphism in the β1-adrenergic receptor gene with the risk of heart failure in humans. Using data from approximately 7000 patients and 3000 healthy controls, we conducted a meta-analysis to examine the effects of β adrenergic receptor polymorphisms on heart failure prognosis, response to β-blocker medication, and susceptibility to heart failure. Given that these investigations reveal disparities in the effects of metoprolol and carvedilol on the two unique phenotypic profiles of the two receptors under investigation, in vivo data also point to variations in the drug –gene interaction between these two β-adrenoceptor blockers. Metoprolol has been demonstrated to primarily interact with the ADRB1 Arg389Gly-polymorpism about LVEF, blood pressure,and heart rate responses, while carvedilol has most consistently been demonstrated to interact with the ADRB2 Gln27Glu-polymorphism. It appears that those with heart failure may benefit from genetic testing for the genotype involving Arg389Gly and Gln27Glu before starting β -adrenoceptor blocker treatment. Since this would provide the best possible treatment choice with the three suggested β-adrenoceptor blockers. Mon, 01 Jan 2024 00:00:00 GMT https://repository.utm.md/handle/5014/26954 2024-01-01T00:00:00Z https://repository.utm.md/handle/5014/26951 Peculiarities in the quantum transport at the interfaces of bismuth-antimony bicrystals CHISTOL, Vitalie; CONDREA, Elena; SIDORENKO, Anatolie As a result of the study of the magnetic and superconducting properties of tilt-type crystallite interfaces in bismuth-antimony bicrystals were detected some properties unusual for their similar bulk semiconductors. A comprehensive study was carried out on the bicrystals with nanoscale multilayer interfaces, where superconductivity (Tc ≤ 21K) is exhibited separately or simultaneously with weak ferromagnetism. Magnetotransport anomalies identified in magnetic field transport manifest themselves in the Hall effect, longitudinal magnetoresistance and Seebeck effect. Behaviour of the Seebeck coefficient and magnetoresistance peculiarities indicate the occurrence of a new small group of the electrons; thermomagnetic phenomena in crystallite interfaces layers exhibit behavior of the 3D topological semimetals, whereas in semiconductor bulk bicrystals they manifest typical features of the 3D topological insulators. Both phenomena indicate to the electronic phase transitions of the semiconductor-semimetal type in magnetic field. Mon, 01 Jan 2024 00:00:00 GMT https://repository.utm.md/handle/5014/26951 2024-01-01T00:00:00Z https://repository.utm.md/handle/5014/26950 The approach of molecular medicine to the treatment of Gaucher disease ROTARU, Ludmila; SIDORENKO, Ludmila Gaucher disease presents a metabolic rare disease with the autosomal recessive transmission. The cause of this monogenic disease is the mutation of the gene GBA. As a consequence of this mutation, a deficiency of synthesis of the enzyme β- gucocerebrosidase occurs. As a result, glucocerebrosides accumulate throughout the body, especially in the bone marrow, spleen and liver. Three different forms of Gaucher disease have been determined, distinguished by the absence or presence and extent of neurological complications. Currently, five therapies for the treatment of Gaucher disease are described. This review study provides the most recent information on the therapies approved for the treatment of the disease. Mon, 01 Jan 2024 00:00:00 GMT https://repository.utm.md/handle/5014/26950 2024-01-01T00:00:00Z https://repository.utm.md/handle/5014/26948 Genetic predispositions in atrial fibrillation: implications for precision medicine ELABID, Wesam; SIDORENKO, Ludmila Focusing on the theme "Aspects of Genetic Predisposition in Atrial Fibrillation," this paper embarks on a meticulous exploration of the intricate interplay between genetic factors and AF. It delineates how genetic predispositions intersect with environmental influences to shape individual susceptibility, disease trajectory, and treatment response. Furthermore, by elucidating the genetic landscape of AF, this research aims to furnish clinicians and researchers with invaluable tools for personalized risk assessment and targeted therapeutic interventions. Ultimately, this comprehensive inquiry into genetic predispositions in AF not only advances our understanding of this complex arrhythmia but also paves the way for precision medicine approaches tailored to individual genetic profiles. By unraveling the genetic dimensions of AF, this study endeavors to catalyze transformative advancements in the prevention, diagnosis, and management of this pervasive cardiovascular condition. Mon, 01 Jan 2024 00:00:00 GMT https://repository.utm.md/handle/5014/26948 2024-01-01T00:00:00Z